DWP-710 is under clinical development by Daewoong Pharmaceutical and currently in Phase II for Acute Respiratory Distress Syndrome. According to GlobalData, Phase II drugs for Acute Respiratory Distress Syndrome have a 31% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how DWP-710’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
DWP-710 is under development for the treatment of acute respiratory distress syndrome (ARDS) and coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The therapeutic candidate comprises of mesenchymal stem cells (MSC). It is administered through intravenous route.
Daewoong Pharmaceutical overview
Daewoong Pharmaceutical, a subsidiary of Daewoong Co Ltd, is a manufacturer and distributor of prescription drugs in South Korea. It offers prescription drugs, quasi drugs, healthcare products and APIs. The company produces products in the form of tablets, capsules, ointments, injections, liquids, and sprays. It offers products for conditions such as bone and joint diseases, cardiovascular diseases, central nervous system diseases, circulatory system, dermatological, gastrointestinal, and respiratory system remedies. It also carries out the development and commercialization of products through in-licensing, co-marketing and co-promotion. The company operates in Japan, the US, Canada, Switzerland, Germany, besides Indonesia, China, Vietnam, Israel, Thailand, and India in Asia. Daewoong Pharmaceutical is headquartered in Seoul, South Korea.
For a complete picture of DWP-710’s drug-specific PTSR and LoA scores, buy the report here.